West Pharmaceutical Services, a global provider of solutions for injectable drug administration, has entered a definitive agreement to sell all manufacturing and supply rights for its SmartDose® 3.5mL On-Body Delivery System, along with associated facilities, to AbbVie for $112.5 million, subject to working capital and other adjustments. The transaction is expected to close in mid-2026, pending customary closing conditions.
West will continue the commercial supply of SmartDose® 3.5mL and fulfill ongoing project commitments prior to the transaction, including milestone-based project payments. SmartDose 3.5mL is projected to account for approximately 4% of West’s revenues in fiscal year 2025, while the company will continue developing and manufacturing other SmartDose versions, including the 10mL On-Body Delivery System for larger-volume injectable therapies.
Headquartered in Exton, Pennsylvania, West Pharmaceutical Services operates 25 manufacturing facilities across 50 global sites and employs over 10,000 staff. The company delivers more than 41 billion components and devices annually, supporting both established and emerging drug developers. In fiscal year 2024, West reported net sales of $2.89 billion.
The sale of SmartDose® 3.5mL aligns with West’s portfolio strategy and its focus on patient-centric, high-growth injectable delivery technologies while enabling AbbVie to expand its capabilities in on-body delivery systems.
Also Read